4/16
10:55 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/15
09:14 am
rnaz
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors [Yahoo! Finance]
4/15
09:00 am
rnaz
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
High
Report
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
4/3
12:11 pm
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/3
09:29 am
rnaz
TransCode Therapeutics Reports 2023 Results; Provides Business Update [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Reports 2023 Results; Provides Business Update [Yahoo! Finance]
4/3
09:10 am
rnaz
TransCode Therapeutics Reports 2023 Results; Provides Business Update
Medium
Report
TransCode Therapeutics Reports 2023 Results; Provides Business Update
3/28
08:40 am
rnaz
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer [Yahoo! Finance]
3/28
08:30 am
rnaz
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Low
Report
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
3/11
09:12 am
rnaz
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment [Yahoo! Finance]
Medium
Report
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment [Yahoo! Finance]
3/11
09:00 am
rnaz
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
High
Report
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
3/6
04:36 pm
rnaz
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress [Yahoo! Finance]
Low
Report
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress [Yahoo! Finance]
2/20
08:12 am
rnaz
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic [Yahoo! Finance]
Low
Report
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic [Yahoo! Finance]
2/20
08:00 am
rnaz
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Medium
Report
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
1/31
04:16 pm
rnaz
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market [Yahoo! Finance]
High
Report
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market [Yahoo! Finance]
1/31
04:05 pm
rnaz
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
Low
Report
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
1/29
08:36 am
rnaz
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer [Yahoo! Finance]
Medium
Report
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer [Yahoo! Finance]
1/29
08:30 am
rnaz
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Low
Report
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer